Company Profile
Lucid Diagnostics Stock Price, News & Analysis
- Ticker:
- LUCD
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Stock performance
0.95 USD (-4.69%)
Close
Last updated: August 6, 2026
196M USD
Market cap
Why the stock is moving
Following the latest company update, “Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test”, LUCD closed up 4.25% at $1.00 on Aug 5, 2026. The move occurred in the trading session associated with this commercial update.
Company overview
Esophageal Cancer Prevention Company
Lucid Diagnostics is a commercial-stage diagnostics subsidiary of PAVmed focused on detecting esophageal precancer in patients with chronic gastroesophageal reflux disease.
EsoGuard and EsoCheck
The EsoGuard DNA test is performed on samples collected with the non-endoscopic EsoCheck cell-collection device. Together, the products are designed to identify at-risk patients before esophageal cancer develops.
Commercial and Reimbursement Model
Lucid generates revenue from processed EsoGuard tests while building adoption through gastroenterologists, health systems, commercial payers, Medicare, and the Veterans Health Administration.
Future catalysts
The main thing to watch at Lucid Diagnostics is its latest development priorities. The update that sharpened the story was the next company-specific pipeline update. That is the part of the story investors will probably keep circling back to.
Recent news
- 01
- 02
Lucid Diagnostics to Participate in Upcoming Investor Conferences
Source: Lucid Diagnostics
- 03
- 04
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
Source: Lucid Diagnostics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Lucid Diagnostics (LUCD)?
Lucid Diagnostics (LUCD) most recently closed at 0.95 USD, a -4.69% move versus the previous session.
What is the market cap of Lucid Diagnostics (LUCD)?
Lucid Diagnostics currently has a market capitalization of 196M USD on BioPharmSignal.
What does Lucid Diagnostics do?
Esophageal Cancer Prevention Company Lucid Diagnostics is a commercial-stage diagnostics subsidiary of PAVmed focused on detecting esophageal precancer in patients with chronic gastroesophageal reflux disease. EsoGuard and EsoCheck The EsoGuard DNA test is performed on samples collected with the non-endoscopic EsoCheck cell-collection device. Together, the...
On which exchange is LUCD stock listed?
Lucid Diagnostics (LUCD) is associated with NASDAQ, United States, MedTech.
What is Esophageal?
Esophageal Cancer Prevention Company Lucid Diagnostics is a commercial-stage diagnostics subsidiary of PAVmed focused on detecting esophageal precancer in patients with chronic gastroesophageal reflux disease.
Which conditions is Lucid Diagnostics targeting with Esophageal?
Lucid Diagnostics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Lucid Diagnostics describe recent progress with Esophageal?
The main thing to watch at Lucid Diagnostics is its latest development priorities. The update that sharpened the story was the next company-specific pipeline update. That is the part of the story investors will probably keep circling back to.
What is Cancer?
Esophageal Cancer Prevention Company Lucid Diagnostics is a commercial-stage diagnostics subsidiary of PAVmed focused on detecting esophageal precancer in patients with chronic gastroesophageal reflux disease.